Development and applications of surface plasmon resonance-based von Willebrand factor-collagen binding assay

Analytical Biochemistry

Volumn 302, Issue 2, 2002, Pages 252-262

  Saenko, Evgueni ^a   Kannicht, Christoph ^b   Loster, Klemens ^b   Sarafanov, Andrey ^a   Khrenov, Alexey ^a   Kouiavskaia, Diana ^a   Shima, Midori ^c   Ananyeva, Natalya ^a   Schwinn, Horst ^d   Gruber, Gerhard ^e   Josic, Djuro ^e  

^a HOLLAND LABORATORY   (United States)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c NARA MEDICAL UNIVERSITY   (Japan)

^d Octapharma AG   (Switzerland)

^e Octapharma Pharmazeutika Produktions GmbH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIVES; BIOASSAY; COLLAGEN; GLYCOPROTEINS; HEAT TREATMENT; PLASMONS; VIRUSES;

DEVELOPMENT AND APPLICATIONS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRICES; FUNCTIONAL ACTIVITIES; RESIDUAL MOISTURE CONTENT; THERAPEUTIC EFFICACY; VIRUS INACTIVATION; VON WILLEBRAND FACTOR;

SURFACE PLASMON RESONANCE;

COLLAGEN; VON WILLEBRAND FACTOR;

ACCURACY; ANALYTIC METHOD; ARTICLE; AUTOMATION; BINDING ASSAY; BIOSENSOR; CORRELATION FUNCTION; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAT TREATMENT; PRIORITY JOURNAL; REPRODUCIBILITY; STRUCTURE ANALYSIS; SURFACE PLASMON RESONANCE; VALIDATION PROCESS; VIRUS INACTIVATION;

EID: 18344390640     PISSN: 00032697     EISSN: None     Source Type: Journal    
DOI: 10.1006/abio.2001.5555     Document Type: Article

References (47)

1. Von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation
2. Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III
3. Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-von Willebrand factor bound to the subendothelium
4. Factor VIII-related protein circulates in normal human plasma as high molecular weight multimers
5. Structure of pre-pro-von Willebrand factor and its expression in heterologous cells
6. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor
7. Interaction of the von Willebrand factor (vWf) with collagen. Localization of the primary collagen-binding site by analysis of recombinant vWf A domain polypeptides
8. Identification of domains responsible for von Willebrand factor Type VI collagen interaction mediating platelet adhesion under high flow
9. Structure-function relationship of the A1 domain of von Willebrand factor
10. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content
11. Biochemical characteristics of therapeutic plasma concentrates used in the treatment of von Willebrand disease
12. Von Willebrand's disease
13. Discrimination of von Willebrand disease (VWD) subtypes: Direct comparison of von Willebrand factor:collagen binding assay (VWF:CBA) with monoclonal antibody (MAB) based VWF-capture systems
14. Laboratory testing for von Willebrand's disease: An assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey
15. Development of a single collagen based ELISA assay aids the diagnosis of, and permits sensitive discrimination between type I and type II, von Willebrand's disease
16. Biological activity of von Willebrand factor during the manufacture of therapeutic factor VIII concentrates as determined by the collagen-binding assay
17. Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII
18. Standards for assay of von Willebrand factor concentrates: A collaborative study
19. Von Willebrand factor: Measuring its antigen or function? Correlation between the level of antigen, activity, and multimer size using various detection systems
20. Human coagulation factor VIII, freeze dried. European Pharmacopoeia Commission Guideline
21. Association of the factor VIII light chain with von Willebrand factor
22. A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor
23. Human von Willebrand factor: A multivalent protein composed of identical subunits
24. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
25. Determination of adequate moisture content for efficient dry-heat viral inactivation in lyophilized factor VIII by loss on drying and by near infrared spectroscopy
26. Development of a single chromogenic factor VIII assay for clinical use
27. Von Willebrand factor activity detected in a monoclonal antibody-based ELISA: An alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use
28. Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis
29. Collagen binding assay for von Willebrand factor (VWF:CBA): Detection of von Willebrand disease (VWD), and discrimination of VWD subtypes, depends on collagen source
30. Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors
31. A simple method for the preparation of homogeneous phospholipid vesicles
32. Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets
33. Molecular modifications in factor VIII concentrates produced from different plasma pools
34. Modification of factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation
35. Binding of human factor VIII to phospholipid vesicles
36. The determination of von Willebrand factor activity by collagen binding assay
37. Detection of von Willebrand disorder and identification of qualitative von Willebrand factor defects
38. Improving biosensor analysis
39. Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors
40. Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100 degrees C
41. Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine
42. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248-2312 which overlap a phospholipid binding site
43. Antigenicity of putative phospholipid membrane-binding residues in factor VIII
44. A role for the C2 domain of factor VIII in binding to von Willebrand factor
45. 1689
46. Role of factor VIII C2 domain in factor VIII binding to factor Xa